BuybackOct 21, 2026, 04:25 PM
Medpace Authorizes New $1.0B Stock Buyback Program
AI Summary
Medpace Holdings, Inc. announced a new $1.0 billion stock repurchase authorization, replacing the previous one which was terminated. The company also reported strong third quarter and year-to-date financial results, with revenue and net income showing significant year-over-year growth. Full-year 2026 revenue guidance was also provided, indicating continued expected growth.
Key Highlights
- Medpace announced a new $1.0 billion stock repurchase authorization, valid until December 31, 2028.
- The previous stock repurchase authorization, with $527.0 million remaining, was terminated effective October 20, 2026.
- Third quarter 2026 revenue increased 8.5% year-over-year to $716.0 million.
- Third quarter 2026 GAAP net income was $137.5 million, or $4.84 per diluted share, up from $111.1 million ($3.86/share) in the prior year.
- Year-to-date 2026 revenue grew 16.9% to $2,129.9 million.
- Year-to-date 2026 GAAP net income was $382.7 million, or $13.37 per diluted share, compared to $316.0 million ($10.64/share) in the prior year.
- Company forecasts 2026 revenue between $2.835 billion and $2.855 billion.
Price Impact
More from MEDP